Elizabeth Kessler
Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 8 | 2026 | 259 | 2.870 |
Why?
| | Prostatic Neoplasms | 14 | 2025 | 972 | 2.830 |
Why?
| | Carcinoma, Renal Cell | 8 | 2023 | 231 | 1.860 |
Why?
| | Kidney Neoplasms | 10 | 2023 | 419 | 1.840 |
Why?
| | Suicide, Assisted | 6 | 2024 | 32 | 1.650 |
Why?
| | Antineoplastic Agents | 11 | 2026 | 2219 | 1.580 |
Why?
| | Prostate-Specific Antigen | 3 | 2021 | 162 | 1.240 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2026 | 1998 | 0.980 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 4 | 2026 | 54 | 0.950 |
Why?
| | Physicians | 6 | 2024 | 955 | 0.920 |
Why?
| | Oncologists | 2 | 2024 | 47 | 0.860 |
Why?
| | Patient Care Planning | 1 | 2026 | 170 | 0.840 |
Why?
| | Patient Preference | 1 | 2025 | 226 | 0.730 |
Why?
| | Aged | 30 | 2026 | 26432 | 0.610 |
Why?
| | Orchiectomy | 3 | 2016 | 72 | 0.600 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1160 | 0.600 |
Why?
| | Anilides | 5 | 2023 | 83 | 0.600 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.570 |
Why?
| | Abiraterone Acetate | 1 | 2017 | 15 | 0.500 |
Why?
| | Plant Extracts | 1 | 2018 | 192 | 0.490 |
Why?
| | Neoplasms | 7 | 2026 | 2954 | 0.490 |
Why?
| | Prednisone | 1 | 2017 | 229 | 0.460 |
Why?
| | Capecitabine | 1 | 2015 | 56 | 0.460 |
Why?
| | Indazoles | 2 | 2014 | 86 | 0.460 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 30 | 0.450 |
Why?
| | Pyridines | 5 | 2023 | 610 | 0.450 |
Why?
| | Neoplasm Metastasis | 6 | 2026 | 693 | 0.440 |
Why?
| | Frailty | 1 | 2018 | 208 | 0.440 |
Why?
| | Humans | 59 | 2026 | 146342 | 0.430 |
Why?
| | Imidazoles | 2 | 2014 | 245 | 0.430 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 57 | 0.430 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 83 | 0.420 |
Why?
| | Deoxycytidine | 1 | 2015 | 219 | 0.420 |
Why?
| | Spinal Neoplasms | 1 | 2014 | 36 | 0.420 |
Why?
| | Quinazolines | 1 | 2015 | 267 | 0.410 |
Why?
| | Piperidines | 1 | 2015 | 225 | 0.410 |
Why?
| | Testicular Neoplasms | 3 | 2023 | 108 | 0.400 |
Why?
| | Immunotherapy | 1 | 2018 | 671 | 0.380 |
Why?
| | Geriatric Assessment | 5 | 2026 | 244 | 0.370 |
Why?
| | Medical Oncology | 3 | 2026 | 345 | 0.360 |
Why?
| | Aged, 80 and over | 9 | 2026 | 8391 | 0.340 |
Why?
| | Canada | 5 | 2023 | 432 | 0.340 |
Why?
| | Male | 32 | 2026 | 73396 | 0.340 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 983 | 0.310 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2015 | 628 | 0.310 |
Why?
| | Surveys and Questionnaires | 9 | 2025 | 6073 | 0.290 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 76 | 0.290 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 721 | 0.280 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2026 | 992 | 0.280 |
Why?
| | Aging | 2 | 2018 | 1996 | 0.270 |
Why?
| | Androgen Antagonists | 3 | 2020 | 91 | 0.270 |
Why?
| | Middle Aged | 18 | 2026 | 36619 | 0.260 |
Why?
| | Age Factors | 4 | 2026 | 3347 | 0.260 |
Why?
| | Palliative Care | 4 | 2026 | 1032 | 0.250 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 944 | 0.250 |
Why?
| | Neoplasm Staging | 5 | 2023 | 1488 | 0.250 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 475 | 0.250 |
Why?
| | Caregivers | 2 | 2023 | 1080 | 0.250 |
Why?
| | Urothelium | 3 | 2019 | 33 | 0.250 |
Why?
| | Communication | 2 | 2024 | 980 | 0.240 |
Why?
| | Delphi Technique | 2 | 2026 | 350 | 0.240 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2019 | 70 | 0.240 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 504 | 0.240 |
Why?
| | Malignant Atrophic Papulosis | 1 | 2025 | 1 | 0.230 |
Why?
| | Treatment Outcome | 8 | 2025 | 11821 | 0.230 |
Why?
| | Carboplatin | 1 | 2026 | 168 | 0.230 |
Why?
| | Stress, Psychological | 1 | 2014 | 1171 | 0.230 |
Why?
| | Phenylurea Compounds | 1 | 2026 | 122 | 0.220 |
Why?
| | Quinolines | 1 | 2026 | 191 | 0.210 |
Why?
| | Biopsy | 3 | 2025 | 1075 | 0.200 |
Why?
| | Penile Neoplasms | 1 | 2023 | 7 | 0.200 |
Why?
| | Subacute Care | 1 | 2024 | 85 | 0.190 |
Why?
| | Terminally Ill | 1 | 2023 | 40 | 0.190 |
Why?
| | Pilot Projects | 5 | 2023 | 1888 | 0.190 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 447 | 0.180 |
Why?
| | Bone Neoplasms | 2 | 2015 | 272 | 0.180 |
Why?
| | Administration, Oral | 1 | 2025 | 872 | 0.180 |
Why?
| | Skilled Nursing Facilities | 1 | 2024 | 152 | 0.180 |
Why?
| | Quality of Life | 4 | 2022 | 3200 | 0.180 |
Why?
| | Female | 18 | 2025 | 79499 | 0.170 |
Why?
| | Adenosine Deaminase | 1 | 2021 | 45 | 0.170 |
Why?
| | Vasculitis | 1 | 2021 | 69 | 0.170 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5899 | 0.170 |
Why?
| | Skin | 1 | 2025 | 701 | 0.160 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2675 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 200 | 0.160 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 241 | 0.160 |
Why?
| | Videoconferencing | 1 | 2020 | 62 | 0.160 |
Why?
| | Ureteral Neoplasms | 1 | 2019 | 1 | 0.150 |
Why?
| | Nephroureterectomy | 1 | 2019 | 2 | 0.150 |
Why?
| | Adult | 11 | 2025 | 41087 | 0.150 |
Why?
| | Hospice Care | 1 | 2022 | 230 | 0.150 |
Why?
| | Physical Examination | 1 | 2020 | 237 | 0.150 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 597 | 0.140 |
Why?
| | Rheumatology | 1 | 2020 | 136 | 0.140 |
Why?
| | Colorado | 3 | 2024 | 4595 | 0.140 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 23 | 0.140 |
Why?
| | United States | 6 | 2025 | 16136 | 0.140 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 64 | 0.140 |
Why?
| | Patient Selection | 2 | 2020 | 728 | 0.130 |
Why?
| | Frail Elderly | 1 | 2018 | 141 | 0.130 |
Why?
| | Wilms Tumor | 1 | 2018 | 91 | 0.130 |
Why?
| | Patient Discharge | 1 | 2024 | 997 | 0.130 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1219 | 0.130 |
Why?
| | Proton Therapy | 1 | 2017 | 16 | 0.130 |
Why?
| | Checklist | 1 | 2018 | 105 | 0.120 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.120 |
Why?
| | Prognosis | 4 | 2023 | 4351 | 0.120 |
Why?
| | Taxoids | 1 | 2017 | 115 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2022 | 348 | 0.120 |
Why?
| | Mass Screening | 2 | 2021 | 1307 | 0.120 |
Why?
| | Nutritional Status | 1 | 2018 | 346 | 0.120 |
Why?
| | Cisplatin | 1 | 2018 | 347 | 0.120 |
Why?
| | Documentation | 1 | 2018 | 202 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2021 | 227 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 365 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2015 | 101 | 0.110 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 49 | 0.100 |
Why?
| | Muscle, Smooth | 1 | 2015 | 152 | 0.100 |
Why?
| | Decision Making | 1 | 2022 | 993 | 0.100 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 881 | 0.100 |
Why?
| | Demography | 1 | 2014 | 274 | 0.100 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 16 | 0.100 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 335 | 0.100 |
Why?
| | Risk Assessment | 2 | 2023 | 3712 | 0.090 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 239 | 0.090 |
Why?
| | Energy Metabolism | 1 | 2018 | 930 | 0.090 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 250 | 0.090 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 522 | 0.090 |
Why?
| | Pediatrics | 1 | 2020 | 1124 | 0.090 |
Why?
| | Feasibility Studies | 3 | 2023 | 1135 | 0.090 |
Why?
| | Bone Diseases | 1 | 2012 | 60 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 861 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.090 |
Why?
| | Drugs, Investigational | 1 | 2011 | 31 | 0.090 |
Why?
| | Clinical Competence | 1 | 2020 | 1272 | 0.090 |
Why?
| | Needs Assessment | 1 | 2014 | 404 | 0.080 |
Why?
| | Health Personnel | 1 | 2018 | 754 | 0.080 |
Why?
| | Radiosurgery | 1 | 2015 | 398 | 0.080 |
Why?
| | Urinary Bladder | 1 | 2013 | 194 | 0.080 |
Why?
| | Telemedicine | 1 | 2020 | 966 | 0.080 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2012 | 215 | 0.080 |
Why?
| | Cohort Studies | 2 | 2026 | 6077 | 0.080 |
Why?
| | Sarcoma | 1 | 2013 | 209 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1512 | 0.080 |
Why?
| | Pyrimidines | 1 | 2014 | 532 | 0.080 |
Why?
| | Disease Progression | 1 | 2018 | 2867 | 0.080 |
Why?
| | Sulfonamides | 1 | 2014 | 594 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1591 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 444 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 663 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 530 | 0.070 |
Why?
| | B7-H1 Antigen | 2 | 2022 | 245 | 0.070 |
Why?
| | Quality Improvement | 1 | 2018 | 1354 | 0.070 |
Why?
| | Survival Rate | 3 | 2019 | 2092 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 1378 | 0.060 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2026 | 69 | 0.060 |
Why?
| | Isoxazoles | 1 | 2026 | 57 | 0.060 |
Why?
| | Pyrazines | 1 | 2026 | 94 | 0.060 |
Why?
| | Nephrectomy | 2 | 2018 | 172 | 0.050 |
Why?
| | Conscience | 1 | 2024 | 9 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10921 | 0.050 |
Why?
| | Drug Interactions | 2 | 2017 | 405 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 91 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2023 | 17438 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2025 | 1271 | 0.050 |
Why?
| | Telephone | 1 | 2023 | 175 | 0.050 |
Why?
| | Morals | 1 | 2023 | 84 | 0.050 |
Why?
| | SEER Program | 1 | 2023 | 233 | 0.040 |
Why?
| | Young Adult | 4 | 2023 | 14330 | 0.040 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2021 | 22 | 0.040 |
Why?
| | Agammaglobulinemia | 1 | 2021 | 36 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 417 | 0.040 |
Why?
| | Adolescent | 4 | 2025 | 22557 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 78 | 0.040 |
Why?
| | Fatigue | 1 | 2023 | 363 | 0.040 |
Why?
| | Prostate | 1 | 2022 | 159 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2021 | 372 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2022 | 5439 | 0.040 |
Why?
| | Europe | 1 | 2020 | 421 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1064 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 738 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 313 | 0.030 |
Why?
| | Central Nervous System | 1 | 2020 | 278 | 0.030 |
Why?
| | Survivors | 1 | 2022 | 526 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 778 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 790 | 0.030 |
Why?
| | Pain | 1 | 2023 | 790 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1331 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 56 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1763 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 876 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 503 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1292 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 150 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 143 | 0.030 |
Why?
| | Cytokines | 1 | 2021 | 2081 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3926 | 0.020 |
Why?
| | beta-Galactosidase | 1 | 2013 | 73 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2020 | 947 | 0.020 |
Why?
| | Breeding | 1 | 2013 | 64 | 0.020 |
Why?
| | Keratins | 1 | 2013 | 57 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2013 | 148 | 0.020 |
Why?
| | Hyperplasia | 1 | 2013 | 164 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 33 | 0.020 |
Why?
| | Organ Specificity | 1 | 2013 | 307 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 117 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 345 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 197 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 125 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2013 | 429 | 0.020 |
Why?
| | Animals | 4 | 2017 | 38107 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1493 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 4093 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 930 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1712 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 636 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1879 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2022 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2134 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2786 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 7109 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1408 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 8123 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2018 | 6460 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1339 | 0.010 |
Why?
| | Pregnancy | 1 | 2018 | 7230 | 0.010 |
Why?
| | Mice | 2 | 2013 | 18297 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3416 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2502 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3545 | 0.010 |
Why?
| | Child | 1 | 2023 | 22693 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4580 | 0.010 |
Why?
|
|
Kessler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|